TITLE

Canada slow on uptake of new cancer drugs

AUTHOR(S)
Kondro, Wayne
PUB. DATE
September 2010
SOURCE
CMAJ: Canadian Medical Association Journal;9/21/2010, Vol. 182 Issue 13, pE668
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article focuses on the study conducted by professor Mike Richards, on behalf of the Secretary of State for Health in Great Britain, wchi ranked 14 developed nations based on drug usage including U.S., France and Spain. According to the study, Canada is on seventh place overall in drug usage and 13th in the use of new cancer drugs and rheumatoid arthritis biologics. Moreover, Richards states in his report that low usage of drugs may indicate that the needs of patients are not effectively met.
ACCESSION #
54103358

 

Related Articles

  • Are You Seeing Drug Shortages in Your Hospital? RE:Connect Bloggers Weigh In.  // ONS Connect;Feb2011, Vol. 26 Issue 2, p18 

    The article presents two blogs, one related to cancer drug shortage in the U.S. by Julia Whiteker, and other related to the drug shortage in Ghana by Miriam Owusu Sekyere.

  • Synthesis of epothilones A and B in solid and solution phase. Nicolaou, K.C.; Winssinger, N. // Nature;5/15/1997, Vol. 387 Issue 6630, p268 

    Reports the first solid-phase synthesis of epothilone A, the total synthesis of epothilone B, and the generation of a small epothilone library. The significance of the cytotoxicity of epothilones against tumor cells; The new possibilities in natural-product synthesis; The potential for a large...

  • An Analysis of Guidance for Proper Usage Document for Oncology Drugs in Japan. Yonemori, Kan; Hirakawa, Akihiro; Ryushima, Yasuaki; Saito, Mari; Yamamoto, Harukaze; Hirata, Taizo; Ando, Masashi; Kodaira, Makoto; Yunokawa, Mayu; Shimizu, Chikako; Tamura, Kenji; Yamamoto, Hiroshi; Fujiwara, Yasuhiro // Pharmaceutical Medicine - New Zealand;2012, Vol. 26 Issue 3, p165 

    Background: Pharmaceutical companies in Japan often provide a unique document called the Guidance for Proper Usage (GPU) to medical oncologists, in order to promote the proper use of an approved drug. Aim: The aim of the study was to examine the content of and current trends in the efficacy and...

  • Repair of cisplatin-DNA adducts in mutants for genes controlling spontaneous and induced mutagenesis in Saccharomyces cerevisiae yeast. Kovaltsova, S. V.; Chernenkov, A. Yu.; Korolev, V. G. // Russian Journal of Genetics;Jan2007, Vol. 43 Issue 1, p84 

    Sensitivity to the lethal action of the anticancer substance cisplatin was studied in the yeast mutants him1, hsm2, hsm3, and hsm6, deficient for repair of spontaneous and induced mutations. The him1 and hsm3 mutants were as resistant to the agent under study as the wild-type strain. The...

  • Genomic instability: Transgenerational effects of anticancer drugs. Muers, Mary // Nature Reviews Genetics;Mar2012, Vol. 13 Issue 3, p148 

    The article reports on the study on the effects of anticancer drugs on mice which were treated with relevant dose, wherein the mutation rate on the offspring were measured using a single-molecule polymerase chain reaction (PCR) and found an increase in mutations in tissues and maternal alleles.

  • Can Mutations in γ-Actin Modulate the Toxicity of Microtubule Targeting Agents? Fojo, Tito // JNCI: Journal of the National Cancer Institute;10/4/2006, Vol. 98 Issue 19, p1345 

    The article examines whether the toxicity of microtubule targeting agents can be modulated by mutations in gamma-actin. Key issues discussed include the suppression of microtubule dynamics through the use of stabilizing and destabilizing agents at low concentrations that kill cells, as well as...

  • The Role of Radiopharmaceuticals in Drug Discovery. Kairemo, Kalevi; Bergström, Kim // Current Radiopharmaceuticals;Jan2008, Vol. 1 Issue 1, p1 

    An introduction to articles published within the issue is presented, including one on the role of systems biology in the development of cancer drugs, another on the application of drug delivery systems and other imaging modalities in tumor targeting compounds, and one on bioengineered chamelid...

  • Lycorine and its Derivatives for Anticancer Drug Design. Lamoral-Theys, D.; Decaestecker, C.; Mathieu, V.; Dubois, J.; Kornienko, A.; Kiss, R.; Evidente, A.; Pottier, L. // Mini Reviews in Medicinal Chemistry;Jan2010, Vol. 10 Issue 1, p41 

    Amaryllidaceae alkaloids are extensively studied for their biological activities in several pharmaceutical areas, including, for example, Alzheimer's disease for which galanthamine has already reached the market. Among this chemical family, lycorine displays very promising anti-tumor properties....

  • IRF-7 is the master regulator of type-I interferon-dependent immune responses. Honda, Kenya; Yanai, Hideyuki; Negishi, Hideo; Asagiri, Masataka; Sato, Mitsuharu; Mizutani, Tatsuaki; Shimada, Naoya; Ohba, Yusuke; Takaoka, Akinori; Yoshida, Nobuaki; Taniguchi, Tadatsugu // Nature;4/7/2005, Vol. 434 Issue 7034, p772 

    The type-I interferon (IFN-a/ß) response is critical to immunity against viruses and can be triggered in many cell types by cytosolic detection of viral infection, or in differentiated plasmacytoid dendritic cells by the Toll-like receptor 9 (TLR9) subfamily, which generates signals via the...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics